91-39-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Nitro 4' Chloro Diphenyl Ether is used as a key intermediate in the synthesis of TR inhibitors for the development of drugs targeting thyroid hormone receptors. Its chemical properties make it a valuable component in creating effective pharmaceutical compounds.

InChI:InChI=1/C12H8ClNO3/c13-9-6-7-12(11(8-9)14(15)16)17-10-4-2-1-3-5-10/h1-8H

Upstream product

• 139-02-6 sodium phenoxide 
• 89-61-2 2,5-dichloronitrobenzene 
• 108-95-2 phenol 
• 41513-04-6 2-chloro-5-bromonitrobenzene 

Downstream Products

• 93-67-4 5-chloro-2-phenoxyaniline 
• 56966-65-5 (4-bromo-phenyl)-(4-chloro-2-nitro-phenyl)-ether 
• 85385-33-7 5-chloro-2-phenoxyphenylisocyanate 
• 195073-74-6 3-Bromo-N-(5-chloro-2-phenoxy-phenyl)-propionamide 
• 195073-79-1 (3-Bromo-propyl)-(5-chloro-2-phenoxy-phenyl)-amine 
• 51230-49-0 2-chlorodibenzofuran 

Relevant academic research and scientific papers

Synthesis method of 5-chlorine-2-phenoxyaniline and Beta molecular sieve used in synthesis method

The invention discloses a synthesis method of 5-chlorine-2-phenoxyaniline. The synthesis method comprises the following steps: 1) heating 2, 5-dichloronitrobenzene to be melted in a solvent-free state, adding a condensation phase transfer catalyst into the melted 2, 5-dichloronitrobenzene, then adding sodium hydroxide and phenol into the mixture and performing a reaction at the temperature of 60-130 DEG C for 3-5h; 2) cooling a reaction product, adding a solvent, hydrazine hydrate and a Beta molecular sieve reduction catalyst into the reaction product, heating the mixture to backflow and performing a reduction reaction; 3) after a backflow reaction in step 2) is ended, performing filtration to obtain the Beta molecular sieve reduction catalyst and filtrate, distilling the filtrate to obtain alcohol in the solvent, cooling to 15-20 DEG C, stirring the mixture for 3-5h, performing separation by crystallization and performing filtration, so as to obtain the 5-chlorine-2-phenoxyaniline asa filter cake. The 5-chlorine-2-phenoxyaniline is synthesized by adopting the method disclosed by the invention, the technical advantages of having no wastes and saving energy are achieved.

Synthesis and biological evaluation of optimized inhibitors of the mitotic kinesin Kif18A

The mitotic spindle, a highly dynamic structure composed of microtubules, mediates the segregation of the previously duplicated genome into the two nascent daughter cells. Errors in this process contribute to pathology including tumor formation. Key for the shape and function of the mitotic spindle are kinesins, molecular motor proteins that convert chemical energy into mechanical work. Due to their fast mode of action, small molecules are valuable tools to dissect the dynamic functions of kinesins during mitosis. In this study, we report the identification of optimized small molecule inhibitors of the mitotic kinesin Kif18A. Using BTB-1, the first identified Kif18A inhibitor, as a lead compound, we synthesized a collection of derivatives. We demonstrate that some of the synthesized derivatives potently inhibited the ATPase activity of Kif18A with a half maximal inhibitory concentration (IC50) value in the low micromolar range. In vitro analysis of a panel of Kif18A-related kinesins revealed that the two most potent compounds show improved selectivity compared to BTB-1. Structure-activity relationship studies identified substituents mediating undesired inhibitory effects on microtubule polymerization. In summary, our study provides key insights into the mechanism of action of BTB-1 and its analogs, which will have a great impact on the further development of highly selective and bioactive Kif18A inhibitors. Since Kif18A is frequently overexpressed in solid tumors, such compounds are not only of great interest for basic research but also have the potential to open up new strategies for the treatment of human diseases.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Synthesis and evaluation of antipsychotic activity of 11-(4-aryl-1- piperazinyl)-dibenz [b, f][1,4] oxazepines and their 8-chloro analogues

Atypical drugs reduce positive and negative symptoms of schizophrenia, without inducing EPS, but they exert other undesirable side effects. We have gone for synthesis of novel derivatives of Loxapine which are devoid of catalepsy and have decreased metabolic demethylation which is the prominent factor for bioavailability of the drug. While doing so we have also been successful in retaining the antipsychotic activity of the drug. Condensation of 8,11-dichlorodibenzoxazepine and 11-chlorodibenzoxazepine with 1-aryl piperazines was carried to give 8-chloro-11-(4-aryl-1-piperazinyl)-dibenz[b,f] [1,4]oxazepines and 11-(4-aryl-1-piperazinyl)-dibenz[b,f][1,4]oxazepines respectively. These derivatives were found as active as Clozapine.

New spermine and spermidine derivatives as potent inhibitors of trypanosoma cruzi trypanothione reductase

Several spermine and spermidine derivatives containing 2-amino diphenylsulfide substituents were prepared and tested for their inhibiting effects on Trypanosoma cruzi trypanothione reductase. IC50 values were assessed between 0.3 and 3 μM. Compound 32 (K(i) = 0.4 μM) is the most potent TR inhibitor described so far.

2-, 3-, 5-, 8-, 10- AND/OR 11-SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PAIN

The present invention provides substituted dibenzoxazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.